The effect of propolis supplementation with weight loss diet in treatment of non-alcoholic fatty liver

The effect of propolis and placebo supplementation with weight loss diet on metabolic status, meta-inflammation, nutritional status and liver function in patients with non-alcoholic fatty liver

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100209003320N21

Enrollment

Registered

2021-07-18

Start date

2021-07-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Supplement group (propolis three capsules of 500 mg per day after each meal) for 8 weeks from Shahdineh Company of Isfahan with weight loss diet.The amount of calor

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Both sexes Age 20-50 years Body mass index (BMI) in the range of 30-40 Kg/m2 Willingness to participate in the study Non-alcoholic fatty liver disease (NAFLD) (grades 1 and 2)

Exclusion criteria

Exclusion criteria: pregnancy, lactation and menopause in women Skin or gastrointestinal allergies to propolis, honey and any bee products Smoking or alcohol use Following a particular diet in the last three months Using synthetic or herbal medicines for weight loss in the last three months Performing weight loss surgery in the past year or strict weight loss diets in the last three months Use antibiotics or supplements affecting liver enzyme levels in the last three months Having symptoms of infectious or inflammatory disease or recent surgery

Design outcomes

Primary

Measure	Time frame
Tumor necrosis factor. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.;MCP-1. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.;Toll-like receptor 4. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.;Fasting Blood Sugar. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.;Insulin. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.;Total cholesterol. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.;Triglyceride. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.;HDL-C. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: enzymatic colorimetric method using spectrophotometer.;HOMA-IR. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.;Body mass index. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.;Waist circumference. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Meter.;Waist-to-hip ratio (WHR). Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.;Waist to Height Ratio (WHtR). Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.;Alanine aminotransferase. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: enzymatic method.;Aspartate aminotransferase. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.;Gamma Glutamyl	—

Measure

Time frame

Tumor necrosis factor. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.;MCP-1. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.;Toll-like receptor 4. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.;Fasting Blood Sugar. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.;Insulin. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.;Total cholesterol. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.;Triglyceride. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.;HDL-C. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: enzymatic colorimetric method using spectrophotometer.;HOMA-IR. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.;Body mass index. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.;Waist circumference. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Meter.;Waist-to-hip ratio (WHR). Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.;Waist to Height Ratio (WHtR). Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.;Alanine aminotransferase. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: enzymatic method.;Aspartate aminotransferase. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.;Gamma Glutamyl

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehrangiz Ebrahimimamagani

Tabriz University of Medical Sciences

mebrahimimameghani@gmail.com+98 41 3334 1113

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026